



## Xgeva

### Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: \_\_\_\_\_ Date: \_\_\_\_\_  
Patient's ID: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_  
Physician's Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Specialty: \_\_\_\_\_ Physician Office Telephone: \_\_\_\_\_ Physician Office Fax: \_\_\_\_\_

**Referring Provider Info:**  Same as Requesting Provider

Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Fax: \_\_\_\_\_ Phone: \_\_\_\_\_

**Rendering Provider Info:**  Same as Referring Provider  Same as Requesting Provider

Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Fax: \_\_\_\_\_ Phone: \_\_\_\_\_

*Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.*

**Required Demographic Information:**

Patient Weight: \_\_\_\_\_ kg  
Patient Height: \_\_\_\_\_ cm

**Drug Information:**

Strength/Measure \_\_\_\_\_ Units  ml  Gm  mg  ea  Un  
Directions(sig) \_\_\_\_\_ Route of administration \_\_\_\_\_  
Dosing frequency \_\_\_\_\_

**Send completed form to: Priority Partners Fax: 1-866-212-4756**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Xgeva SGM 2152-A – 04/2023.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076**

**Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com**

**Site of Service Questions:**

- A. Indicate the site of service requested:  
 On Campus Outpatient Hospital  Off Campus Outpatient Hospital  
 Home based setting, *skip to Criteria Questions*  Community office, *skip to Criteria Questions*  
 Ambulatory infusion site, *skip to Criteria Questions*
- B. Is the patient less than 18 years of age?  
 Yes, *skip to Clinical Criteria Questions*  
 No
- C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  Yes, *skip to Clinical Criteria Questions*  No
- D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  
 Yes, *skip to Clinical Criteria Questions*  No
- E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  
 Yes, *skip to Clinical Criteria Questions*  No
- F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  
 Yes, *skip to Clinical Criteria Questions*  No
- G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  
 Yes, *skip to Clinical Criteria Questions*  No
- H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?  
***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***  Yes  No

**Clinical Criteria Questions:**

1. What is the diagnosis?  
 Giant cell tumor of the bone  
 Prevention of skeletal-related events due to multiple myeloma or bone metastases from solid tumors (e.g., breast cancer, non-small cell lung cancer, thyroid carcinoma, kidney cancer, prostate cancer)  
 Palliative care for bone metastases from thyroid carcinoma  
 Hypercalcemia of malignancy  
 Treatment for osteopenia or osteoporosis in patients with systemic mastocytosis  
 Other \_\_\_\_\_
2. What is the ICD-10 code? \_\_\_\_\_
3. Is the request for continuation of therapy with the requested medication?  
 Yes  No *If No, skip to diagnosis section.*

**Send completed form to: Priority Partners Fax: 1-866-212-4756**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Xgeva SGM 2152-A – 04/2023.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076**

**Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com**

4. Is the patient experiencing a benefit from therapy with the requested medication as evidenced by disease stability or disease improvement?  Yes  No *No further questions.*

***Complete the following section based on the patient's diagnosis, if applicable.***

**Section A: Hypercalcemia of Malignancy**

5. Is the patient's condition refractory to IV bisphosphonate therapy?  
*If Yes, no further questions.*  Yes  No
6. Is there a clinical reason to avoid treatment with an IV bisphosphonate (e.g., acute renal impairment, renal insufficiency [creatinine clearance < 35 ml/min], history of intolerance to an IV bisphosphonate)?  
 Yes  No

**Section B: Treatment for Osteopenia or Osteoporosis in Patients with Systemic Mastocytosis**

7. Is the patient refractory to bisphosphonate therapy and will be using the requested medication as second-line therapy? *If Yes, no further questions.*  Yes  No
8. Is the patient not a candidate for bisphosphonate therapy because of renal insufficiency?  
 Yes  No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.***

**X**

\_\_\_\_\_  
**Prescriber or Authorized Signature**

\_\_\_\_\_  
**Date (mm/dd/yy)**

**Send completed form to: Priority Partners Fax: 1-866-212-4756**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Xgeva SGM 2152-A – 04/2023.

**Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076**

**Phone: 888-819-1043 • Fax: 1-866-212-4756 • [www.jhhc.com](http://www.jhhc.com)**